File size: 11,625 Bytes

# AntiBERTa2 License 
Version 1.0, December 2023 [Alchemab](http://alchemab.com)

AntiBERTa2 models are antibody-specific Large Language Models (LLM) developed by Alchemab Therapeutics Ltd. Currently AntiBERTa2 includes the following two architectures referred to as AntiBERTa2 (202 M parameters) and AntiBERTa2-CSSP (202 M parameters). Based on the RoFormer LLM from natural language processing, AntiBERTa2 is pre-trained using MLM on 779.4 million unpaired and paired antibody sequences. AntiBERTa2-CSSP refers to a multimodal version of the AntiBERTa2 LLM that leverages the contrastive pre-training objective from the CLIP method; over 1000 antibody crystal structures from the Protein Data Bank were used. After pre-training, AntiBERTa2 develops a rich representation of antibody sequences that can be leveraged for an extensive range of tasks, including (without limitation) antigen binding prediction.

Alchemab Therapeutics is making AntiBERTa2, specifically its parameter weights, available for use, reproduction and distribution under this modified version of the Apache 2.0 Licence. 

## LICENSE SUMMARY
| Permissions | Limitations | Conditions |
| ----------- | ----------  | ---------- |
| Private use | No commercial use | Attaching this license |
| Research and academic use | No use for pre-clinical or clinical tests or studies | Notices |
| Generating and synthesising antibodies | No developing, generating, or synthesising reagent, diagnostic or therapeutic antibodies for *in vitro* or *in vivo* studies | Attribution | 
| Reproduction | "as is" warranties | |
| Modification | No liability | |
| Distribution | | 


## TERMS AND CONDITIONS FOR USE, REPRODUCTIONAND DISTRIBUTION OF ANTIBERTA2
1. Definitions.
"License" shall mean these terms and conditions for use, reproduction, and distribution of the Work as defined by Sections 1 through 9 of this document.
"Licensor" shall mean Alchemab Therapeutics Ltd, the copyright owner or entity authorized by the copyright owner that is granting the License.
"Legal Entity" shall mean the union of the acting entity and all other entities that control, are controlled by, or are under common control with that entity. For the purposes of this definition, "control" means (i) the power, direct or indirect, to cause the direction or management of such entity, whether by contract or otherwise, or (ii) ownership of fifty percent (50%) or more of the outstanding shares, or (iii) beneficial ownership of such entity.
"You" (or "Your") shall mean an individual or Legal Entity exercising permissions granted by this License.
"Source" form shall mean the preferred form for making modifications, including but not limited to software source code, documentation source, and configuration files.
"Object" form shall mean any form resulting from mechanical transformation or translation of a Source form, including but not limited to compiled object code, generated documentation, and conversions to other media types.
"Weights” shall mean all trained parameters of a AntiBERTa2 LLM.
“Work” shall mean the Source or Object form of any of the AntiBERTa2  models, together with the Weights and associated code for deploying those models, which is made available under this License.
"Derivative Works" shall mean any work, whether in Source or Object form, that is based on (or derived from) the Work or any part thereof and for which the editorial revisions, annotations, elaborations, or other modifications represent, as a whole, an original work of authorship. For the purposes of this License, Derivative Works shall not include works that remain separable from, or merely link (or bind by name) to the interfaces of, the Work and Derivative Works thereof.
"Contribution" shall mean any work of authorship, including the original version of the Work and any modifications or additions to that Work or Derivative Works thereof, that is intentionally submitted to Licensor for inclusion in the Work by the copyright owner or by an individual or Legal Entity authorized to submit on behalf of the copyright owner. For the purposes of this definition, "submitted" means any form of electronic, verbal, or written communication sent to the Licensor or its representatives, including but not limited to communication on electronic mailing lists, source code control systems, and issue tracking systems that are managed by, or on behalf of, the Licensor for the purpose of discussing and improving the Work, but excluding communication that is conspicuously marked or otherwise designated in writing by the copyright owner as "Not a Contribution."
"Contributor" shall mean Licensor and any individual or Legal Entity on behalf of whom a Contribution has been received by Licensor and subsequently incorporated within the Work.

2. Grant of Copyright License. Subject to the terms and conditions of this License, each Contributor hereby grants to You a perpetual, worldwide, non-exclusive, no-charge, royalty-free, irrevocable copyright license to reproduce, prepare Derivative Works of, publicly display, publicly perform, and distribute the Work and such Derivative Works in Source or Object form, and for other uses, including (but not limited to) generating antibodies, provided always that such rights are for non-commercial research and academic purposes only. 

3. Grant of Patent License. Subject to the terms and conditions of this License, each Contributor hereby grants to You a perpetual, worldwide, non-exclusive, no-charge, royalty-free, irrevocable (except as stated in this section) patent license to use and transfer the Work, and for other uses, including (but not limited to) generating antibodies, provided always that such rights are for non-commercial research and academic purposes only, where such license applies only to those patent claims licensable by such Contributor that are necessarily infringed by their Contribution(s) alone or by combination of their Contribution(s) with the Work to which such Contribution(s) was submitted. If You institute patent litigation against any entity (including a cross-claim or counterclaim in a lawsuit) alleging that the Work or a Contribution incorporated within the Work constitutes direct or contributory patent infringement, then any patent licenses granted to You under this License for that Work shall terminate as of the date such litigation is filed.

4. License Exclusions. This License, specifically as described in sections 2 and 3, does NOT extend to any commercial use, pre-clinical or clinical tests or studies, or use for the purpose of developing, generating or synthesising reagent, diagnostic or therapeutic antibodies for in vitro or in vivo studies or trials, in relation to the Work or any generated antibodies, whether currently intended, contemplated or foreseeable or not.
If You want to extend the License to cover any of the aforementioned exclusions, please contact the Licensor at this email address: [info@alchemab.com](mailto:info@alchemab.com).

5. Redistribution. You may reproduce and distribute copies of the Work or Derivative Works thereof in any medium, without modifications, and in Source or Object form, provided that You meet the following conditions:
* You must give any other recipients of the Work or Derivative Works a copy of this License, which will apply to the use of the Work or such Derivative Works including (without limitation) the limitations and exclusions to the License; and
* You must cause any modified files to carry prominent notices stating that You changed the files; and
* You must retain, in the Source form of any Derivative Works that You distribute, all copyright, patent, trademark, and attribution notices from the Source form of the Work, excluding those notices that do not pertain to any part of the Derivative Works; and
* If the Work includes a "NOTICE" text file as part of its distribution, then any Derivative Works that You distribute must include a readable copy of the attribution notices contained within such NOTICE file, excluding those notices that do not pertain to any part of the Derivative Works, in at least one of the following places: within a NOTICE text file distributed as part of the Derivative Works; within the Source form or documentation, if provided along with the Derivative Works; or, within a display generated by the Derivative Works, if and wherever such third-party notices normally appear. The contents of the NOTICE file are for informational purposes only and do not modify the License. You must include an attribution to Alchemab Therapeutics. You may also add Your own attribution notices within Derivative Works that You distribute, alongside or as an addendum to the NOTICE text from the Work, provided that such additional attribution notices cannot be construed as modifying the License.

You may add Your own copyright statement to Your modifications.

6. Submission of Contributions. Unless You explicitly state otherwise, any Contribution intentionally submitted for inclusion in the Work by You to the Licensor shall be under the terms and conditions of this License, without any additional terms or conditions. Notwithstanding the above, nothing herein shall supersede or modify the terms of any separate license agreement you may have executed with Licensor regarding such Contributions.

7. Trademarks. This License does not grant permission to use the trade names, trademarks, service marks, or product names of the Licensor, except as required for reasonable and customary use in describing the origin of the Work and reproducing the content of the NOTICE file.

8. Disclaimer of Warranty. Unless required by applicable law or agreed to in writing, Licensor provides the Work (and each Contributor provides its Contributions) on an "AS IS" BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied, including, without limitation, any warranties or conditions of TITLE, NON-INFRINGEMENT, MERCHANTABILITY, or FITNESS FOR A PARTICULAR PURPOSE. You are solely responsible for determining the appropriateness of using or redistributing the Work and assume any risks associated with Your exercise of permissions under this License.

9. Limitation of Liability. In no event and under no legal theory, whether in tort (including negligence), contract, or otherwise, unless required by applicable law (such as deliberate and grossly negligent acts) or agreed to in writing, shall any Contributor be liable to You for damages, including any direct, indirect, special, incidental, or consequential damages of any character arising as a result of this License or out of the use or inability to use the Work (including but not limited to damages for loss of goodwill, work stoppage, computer failure or malfunction, or any and all other commercial damages or losses), even if such Contributor has been advised of the possibility of such damages.

END OF TERMS AND CONDITIONS

## COPYRIGHT NOTICE

Copyright 2023 Alchemab Therapeutics Ltd

Licensed under the AntiBERTa2 License, Version 1.0 (the "License");
you may not use this file except in compliance with the License.
You may obtain a copy of the License at [https://huggingface.co/alchemab/antiberta2/blob/main/LICENSE.md](https://huggingface.co/alchemab/antiberta2/blob/main/LICENSE.md).
Unless required by applicable law or agreed to in writing, the AntiBERTa2 models distributed under the License are distributed on an "AS IS" BASIS,
WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied.
See the License for the specific language governing permissions and
limitations under the License.